Analyst Price Targets — UTHR
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| April 10, 2026 12:54 pm | Terence Flynn | Morgan Stanley | $519.00 | $570.48 | TheFly | United Therapeutics price target raised to $519 from $471 at Morgan Stanley |
| April 10, 2026 9:39 am | — | Raymond James | $700.00 | $570.48 | TheFly | United Therapeutics initiated with an Outperform at Raymond James |
| March 12, 2026 1:11 pm | Olivia Brayer | Cantor Fitzgerald | $625.00 | $541.60 | StreetInsider | United Therapeutics Corp. (UTHR) PT Raised to $625 at Cantor Fitzgerald on IPF Potential |
| February 26, 2026 5:23 pm | Andrew Fein | H.C. Wainwright | $600.00 | $508.47 | StreetInsider | United Therapeutics Corp. (UTHR) PT Raised to $600 at H.C. Wainwright |
| January 6, 2026 1:38 pm | — | UBS | $645.00 | $506.79 | TheFly | United Therapeutics price target raised to $645 from $600 at UBS |
| November 19, 2025 9:24 am | Eun Yang | Jefferies | $575.00 | $476.59 | StreetInsider | Jefferies Reiterates Buy Rating on United Therapeutics Corp. (UTHR) |
| October 30, 2025 1:34 pm | Andrew Fein | H.C. Wainwright | $525.00 | $449.76 | TheFly | United Therapeutics price target raised to $525 from $500 at H.C. Wainwright |
| October 30, 2025 1:32 pm | Lisa Walter | RBC Capital | $587.00 | $449.76 | TheFly | United Therapeutics price target raised to $587 from $569 at RBC Capital |
| October 29, 2025 4:13 pm | Terrance Flynn | Morgan Stanley | $447.00 | $449.70 | StreetInsider | United Therapeutics (UTHR) PT Raised to $447 at Morgan Stanley |
| October 10, 2025 12:07 pm | Terence Flynn | Morgan Stanley | $435.00 | $445.38 | TheFly | United Therapeutics price target raised to $435 from $328 at Morgan Stanley |
Latest News for UTHR
Asset Management One Co. Ltd. decreased its stake in shares of United Therapeutics Corporation (NASDAQ: UTHR) by 5.1% during the undefined quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 23,267 shares of the biotechnology company's stock after selling 1,243 shares during the
Investors with an interest in Medical - Drugs stocks have likely encountered both Catalyst Pharmaceutical (CPRX) and United Therapeutics (UTHR). But which of these two stocks is more attractive to value investors?
SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced that 11 new data presentations across its commercial and development portfolio will be presented at the International Society for Heart and Lung Transplantation (ISHLT) 46th Annual Meeting and Scientific Sessions taking place April 22-25, 2026, in Toronto,…
United Therapeutics Corporation (NASDAQ: UTHR - Get Free Report) Director Christopher Patusky sold 1,000 shares of the business's stock in a transaction that occurred on Friday, April 17th. The shares were sold at an average price of $578.88, for a total transaction of $578,880.00. Following the transaction, the director directly owned 1,490 shares of the company's
United Therapeutics Corporation (NASDAQ: UTHR - Get Free Report) EVP Paul Mahon sold 8,300 shares of the stock in a transaction that occurred on Thursday, April 16th. The stock was sold at an average price of $576.82, for a total value of $4,787,606.00. Following the transaction, the executive vice president directly owned 45,172 shares of the
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for UTHR.
U.S. House Trading
House Trades Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.